Keyphrases
Angiogenic
11%
Anticoagulant Therapy
22%
Anticoagulation Treatment
11%
Circulating Levels
11%
Clinically Indicated
11%
During Pregnancy
100%
Gestational Age
11%
Healthy Pregnant Women
11%
Heparin Therapy
100%
Low Molecular Weight Heparin
100%
Maternal Plasma
22%
Placenta-mediated Pregnancy Complications
22%
Placental Growth Factor (PlGF)
100%
Plasma Concentration
11%
Plasma Samples
11%
Pregnancy Complications
11%
Pregnant Women
44%
Prospective Cohort Study
11%
Soluble Endoglin
33%
Soluble Fms-like Tyrosine kinase-1 (sFlt-1)
44%
Third Trimester
11%
Thromboprophylaxis
11%
Treatment Control
11%
Treatment Group
11%
Medicine and Dentistry
Anticoagulant Therapy
22%
Anticoagulation
11%
Complication of Pregnancy
11%
Endoglin
33%
Enzyme Linked Immunosorbent Assay
11%
Gestational Age
11%
Group Therapy
11%
Heparinization
100%
Low Molecular Weight Heparin
100%
Maternal Plasma
22%
Placenta
22%
Placental Growth Factor
100%
Pregnancy
22%
Prospective Cohort Study
11%
Protein Tyrosine Kinase
44%
Recurrent Disease
11%
Third Trimester Pregnancy
11%
Thromboprophylaxis
11%
Biochemistry, Genetics and Molecular Biology
Anticoagulation
33%
Blood Level
11%
Endoglin
33%
Heparin
100%
Molecular Weight
100%
Placental Growth Factor
100%
Pregnancy
22%
Prospective Cohort Study
11%
Soluble Fms-Like Tyrosine Kinase-1
44%
Third Trimester Pregnancy
11%
Immunology and Microbiology
Anticoagulation
33%
Blood Level
11%
ELISA
11%
Endoglin
33%
Maternal Plasma
22%
Molecular Weight
100%
Placenta
22%
Placental Growth Factor
100%
Pregnancy
22%
Third Trimester Pregnancy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulation Therapy
22%
Endoglin
33%
Enzyme-Linked Immunosorbent Assay
11%
Low Molecular Weight Heparin
100%
Placental Growth Factor
100%
Prospective Cohort Study
11%
Protein Tyrosine Kinase
44%
Recurrent Disease
11%